Inclusion Criteria:

          -  Patients with multiple myeloma who demonstrate evidence of serologic
             relapse/progression while on lenalidomide maintenance given as part of first line
             therapy (including upfront high-dose chemotherapy followed by autologous hematopoietic
             cell transplantation (HCT)) without symptomatic relapse/progression. Lenalidomide
             maintenance is defined as single agent lenalidomide therapy of any doses up to 10 mg
             PO daily for up to 28 days (28-day cycle).

          -  Male or female patients aged ≥ 18 years old

          -  Ability to provide written informed consent obtained prior to participation in the
             study and any related procedures being performed

          -  Measurable disease as outlined in protocol guidelines

          -  Participants must meet laboratory criteria as outlined in protocol guidelines

        Exclusion Criteria:

          -  Prior Elotuzumab

          -  Patients with clinical relapse/progression as per the International Myeloma Working
             Group (IMWG) Uniform Response Criteria for Multiple Myeloma defined as one or more of
             the following criteria:

               -  Development of new soft tissue plasmacytomas or bone lesions (osteoporotic
                  fractures do not constitute progression)

               -  Definite increase in the size of existing plasmacytomas or bone lesions. A
                  definite increase is defined as a 50% (and ≥1 cm) increase as measured serially
                  of the measurable lesion

               -  Hypercalcemia (>11 mg/dL);

               -  Decrease in hemoglobin of ≥2 g/dL not related to therapy or other
                  non-myeloma-related conditions;

               -  Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and
                  attributable to myeloma

               -  Hyperviscosity related to serum paraprotein

          -  Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
             not using an effective method of birth control. Women of childbearing potential must
             have a negative serum pregnancy testing within 7 days prior to the administration of
             drug.

          -  Male patients whose sexual partners are WOCBP not using effective birth control

          -  Patients with a prior malignancy with in the last 5 years (except for basal or
             squamous cell carcinoma, or in situ cancer of the cervix)

          -  Patients with known positivity for human immunodeficiency virus (HIV)) or hepatitis C;
             baseline testing for HIV and hepatitis C is not required

          -  Patients with a diagnosis of POEMS syndrome (polyneuropathy, organomegaly,
             endocrinopathy, monoclonal protein, and skin changes) or plasma cell leukemia (> 2.0 ×
             10^9/L circulating plasma cells by standard differential)